Evidence map›Paper›PMID 26064196›Full record

ReviewInternational journal of clinical and experimental medicine2015

Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis.

Quan Zhou, Aihua Chen, Huamei Song, Jing Tao, Huaijie Yang, Manzhen Zuo

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Advances in Prostate Cancer Biomarkers and Probes.Cyborg and bionic systems (Washington, D.C.) · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Quan ZhouDepartment of Gynecology and Obstetrics, The People's Hospital of Three Gorges University/The First People's Hospital of Yichang Yichang 443000, China.
Aihua ChenDepartment of Gynecology and Obstetrics, The People's Hospital of Three Gorges University/The First People's Hospital of Yichang Yichang 443000, China.
Huamei SongDepartment of Gynecology and Obstetrics, The People's Hospital of Three Gorges University/The First People's Hospital of Yichang Yichang 443000, China.
Jing TaoDepartment of Gynecology and Obstetrics, The People's Hospital of Three Gorges University/The First People's Hospital of Yichang Yichang 443000, China.
Huaijie YangDepartment of Gynecology and Obstetrics, The People's Hospital of Three Gorges University/The First People's Hospital of Yichang Yichang 443000, China.
Manzhen ZuoDepartment of Gynecology and Obstetrics, The People's Hospital of Three Gorges University/The First People's Hospital of Yichang Yichang 443000, China.
Yichang Central People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the association between CD133 expression and prognosis and clinicopathological features of ovarian cancer.

methodsThe electronic and manual searches were performed through the database of PubMed Chinese Wanfang databases (up to September 15, 2014) was performed using the following keywords ovarian cancer, CD133, AC133, prominin-1. Meta-analysis was performed by using Review Manager 5.2 and the outcomes included the overall survival and various clinicopathological features.

resultsA total of 1051 ovarian cancer patients from 8 studies were included. Meta-analysis showed that overexpression of CD133 was highly correlated with reduced 2-year overall survival (OR = 1.67, 95% CI: 1.06-2.63, P = 0.03, fixed-effect). With respect to clinicopathological features, CD133 level was positively correlated with tumor stage (OR = 0.26, 95% CI: 0.12-0.58, P = 0.001 random-effect). But not correlated with patients' age (OR = 1.12, 95% CI: 0.68-1.86, P = 0.65 fixed-effect), tumor grade (OR = 1.20, 95% CI: 0.06-1.62, P = 0.17 random-effect), histological type (OR = 1.10, 95% CI: 0.82-1.47, P = 0.54 fixed-effect) and response to treatment (OR = 0.84, 95% CI: 0.61-1.16, P = 0.29 fixed-effect).

conclusionOn the basis of current retrospective evidence, the present meta-analysis indicated that high level of CD133 expression trends to correlate with a worse prognosis in patients with ovarian cancer.

Indexed as

cancer stem cellsCD133Ovarian cancerprognosis

Identifiers

PMID26064196
PMCPMC4443030
OpenAlexW2407454067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.